nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—kidney cancer	0.571	1	CbGaD
Gliclazide—ALB—Erlotinib—kidney cancer	0.0268	0.308	CbGbCtD
Gliclazide—CYP2C9—Capecitabine—kidney cancer	0.0211	0.243	CbGbCtD
Gliclazide—CYP2C19—Sorafenib—kidney cancer	0.0141	0.162	CbGbCtD
Gliclazide—CYP2C9—Paclitaxel—kidney cancer	0.0132	0.152	CbGbCtD
Gliclazide—CYP2C9—Sorafenib—kidney cancer	0.0118	0.135	CbGbCtD
Gliclazide—CYP2C19—urine—kidney cancer	0.00108	0.222	CbGeAlD
Gliclazide—CYP2C9—urine—kidney cancer	0.000834	0.172	CbGeAlD
Gliclazide—VEGFA—nephron tubule—kidney cancer	0.000762	0.157	CbGeAlD
Gliclazide—VEGFA—cortex of kidney—kidney cancer	0.000652	0.135	CbGeAlD
Gliclazide—VEGFA—cardiac atrium—kidney cancer	0.00062	0.128	CbGeAlD
Gliclazide—ABCC8—renal system—kidney cancer	0.000456	0.0943	CbGeAlD
Gliclazide—ABCC8—kidney—kidney cancer	0.000441	0.0911	CbGeAlD
Gliclazide—Chlorpropamide—PTGS1—kidney cancer	0.000268	0.551	CrCbGaD
Gliclazide—Chlorpropamide—ABCB1—kidney cancer	0.000131	0.268	CrCbGaD
Gliclazide—Diplopia—Doxorubicin—kidney cancer	9.15e-05	0.00042	CcSEcCtD
Gliclazide—Osteoarthritis—Doxorubicin—kidney cancer	9.15e-05	0.00042	CcSEcCtD
Gliclazide—Paraesthesia—Gemcitabine—kidney cancer	9.12e-05	0.000419	CcSEcCtD
Gliclazide—Flushing—Capecitabine—kidney cancer	9.11e-05	0.000419	CcSEcCtD
Gliclazide—Cough—Paclitaxel—kidney cancer	9.09e-05	0.000418	CcSEcCtD
Gliclazide—Asthenia—Sunitinib—kidney cancer	9.08e-05	0.000417	CcSEcCtD
Gliclazide—Dyspnoea—Gemcitabine—kidney cancer	9.05e-05	0.000416	CcSEcCtD
Gliclazide—Nausea—Vinblastine—kidney cancer	9.03e-05	0.000415	CcSEcCtD
Gliclazide—Somnolence—Gemcitabine—kidney cancer	9.03e-05	0.000415	CcSEcCtD
Gliclazide—Convulsion—Paclitaxel—kidney cancer	9.03e-05	0.000415	CcSEcCtD
Gliclazide—Nausea—Everolimus—kidney cancer	9e-05	0.000414	CcSEcCtD
Gliclazide—Diarrhoea—Sorafenib—kidney cancer	9e-05	0.000414	CcSEcCtD
Gliclazide—Hypertension—Paclitaxel—kidney cancer	8.99e-05	0.000413	CcSEcCtD
Gliclazide—Pruritus—Sunitinib—kidney cancer	8.95e-05	0.000411	CcSEcCtD
Gliclazide—Arthralgia—Paclitaxel—kidney cancer	8.87e-05	0.000408	CcSEcCtD
Gliclazide—Chest pain—Paclitaxel—kidney cancer	8.87e-05	0.000408	CcSEcCtD
Gliclazide—Myalgia—Paclitaxel—kidney cancer	8.87e-05	0.000408	CcSEcCtD
Gliclazide—Anxiety—Paclitaxel—kidney cancer	8.84e-05	0.000406	CcSEcCtD
Gliclazide—Hypersensitivity—Dactinomycin—kidney cancer	8.83e-05	0.000406	CcSEcCtD
Gliclazide—Glyburide—ABCB1—kidney cancer	8.82e-05	0.181	CrCbGaD
Gliclazide—Chills—Capecitabine—kidney cancer	8.81e-05	0.000405	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	8.81e-05	0.000405	CcSEcCtD
Gliclazide—Arrhythmia—Capecitabine—kidney cancer	8.77e-05	0.000403	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Gemcitabine—kidney cancer	8.77e-05	0.000403	CcSEcCtD
Gliclazide—Discomfort—Paclitaxel—kidney cancer	8.76e-05	0.000403	CcSEcCtD
Gliclazide—Fatigue—Gemcitabine—kidney cancer	8.76e-05	0.000402	CcSEcCtD
Gliclazide—Gastrointestinal pain—Vincristine—kidney cancer	8.75e-05	0.000402	CcSEcCtD
Gliclazide—Dizziness—Sorafenib—kidney cancer	8.7e-05	0.0004	CcSEcCtD
Gliclazide—Constipation—Gemcitabine—kidney cancer	8.68e-05	0.000399	CcSEcCtD
Gliclazide—Pain—Gemcitabine—kidney cancer	8.68e-05	0.000399	CcSEcCtD
Gliclazide—Nausea—Erlotinib—kidney cancer	8.68e-05	0.000399	CcSEcCtD
Gliclazide—Dry mouth—Paclitaxel—kidney cancer	8.67e-05	0.000399	CcSEcCtD
Gliclazide—Diarrhoea—Sunitinib—kidney cancer	8.66e-05	0.000398	CcSEcCtD
Gliclazide—Mental disorder—Capecitabine—kidney cancer	8.6e-05	0.000395	CcSEcCtD
Gliclazide—Asthenia—Dactinomycin—kidney cancer	8.6e-05	0.000395	CcSEcCtD
Gliclazide—Confusional state—Paclitaxel—kidney cancer	8.57e-05	0.000394	CcSEcCtD
Gliclazide—Erythema—Capecitabine—kidney cancer	8.55e-05	0.000393	CcSEcCtD
Gliclazide—Malnutrition—Capecitabine—kidney cancer	8.55e-05	0.000393	CcSEcCtD
Gliclazide—Abdominal pain—Vincristine—kidney cancer	8.46e-05	0.000389	CcSEcCtD
Gliclazide—Body temperature increased—Vincristine—kidney cancer	8.46e-05	0.000389	CcSEcCtD
Gliclazide—Infection—Paclitaxel—kidney cancer	8.45e-05	0.000388	CcSEcCtD
Gliclazide—Flatulence—Capecitabine—kidney cancer	8.42e-05	0.000387	CcSEcCtD
Gliclazide—Dry skin—Doxorubicin—kidney cancer	8.39e-05	0.000385	CcSEcCtD
Gliclazide—Dizziness—Sunitinib—kidney cancer	8.37e-05	0.000385	CcSEcCtD
Gliclazide—Feeling abnormal—Gemcitabine—kidney cancer	8.37e-05	0.000385	CcSEcCtD
Gliclazide—Vomiting—Sorafenib—kidney cancer	8.36e-05	0.000384	CcSEcCtD
Gliclazide—Nervous system disorder—Paclitaxel—kidney cancer	8.34e-05	0.000383	CcSEcCtD
Gliclazide—Thrombocytopenia—Paclitaxel—kidney cancer	8.32e-05	0.000383	CcSEcCtD
Gliclazide—Tachycardia—Paclitaxel—kidney cancer	8.3e-05	0.000381	CcSEcCtD
Gliclazide—Rash—Sorafenib—kidney cancer	8.29e-05	0.000381	CcSEcCtD
Gliclazide—Dermatitis—Sorafenib—kidney cancer	8.29e-05	0.000381	CcSEcCtD
Gliclazide—Back pain—Capecitabine—kidney cancer	8.27e-05	0.00038	CcSEcCtD
Gliclazide—Skin disorder—Paclitaxel—kidney cancer	8.26e-05	0.000379	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	8.24e-05	0.000379	CcSEcCtD
Gliclazide—Headache—Sorafenib—kidney cancer	8.24e-05	0.000379	CcSEcCtD
Gliclazide—Hyperhidrosis—Paclitaxel—kidney cancer	8.22e-05	0.000378	CcSEcCtD
Gliclazide—Diarrhoea—Dactinomycin—kidney cancer	8.2e-05	0.000377	CcSEcCtD
Gliclazide—Gastritis—Doxorubicin—kidney cancer	8.1e-05	0.000372	CcSEcCtD
Gliclazide—Vomiting—Sunitinib—kidney cancer	8.05e-05	0.00037	CcSEcCtD
Gliclazide—Body temperature increased—Gemcitabine—kidney cancer	8.03e-05	0.000369	CcSEcCtD
Gliclazide—Tremor—Capecitabine—kidney cancer	8.01e-05	0.000368	CcSEcCtD
Gliclazide—Rash—Sunitinib—kidney cancer	7.98e-05	0.000367	CcSEcCtD
Gliclazide—Dermatitis—Sunitinib—kidney cancer	7.97e-05	0.000366	CcSEcCtD
Gliclazide—Abdominal distension—Doxorubicin—kidney cancer	7.96e-05	0.000366	CcSEcCtD
Gliclazide—Hypotension—Paclitaxel—kidney cancer	7.94e-05	0.000365	CcSEcCtD
Gliclazide—Ill-defined disorder—Capecitabine—kidney cancer	7.93e-05	0.000364	CcSEcCtD
Gliclazide—Headache—Sunitinib—kidney cancer	7.93e-05	0.000364	CcSEcCtD
Gliclazide—Asthma—Doxorubicin—kidney cancer	7.91e-05	0.000363	CcSEcCtD
Gliclazide—Anaemia—Capecitabine—kidney cancer	7.9e-05	0.000363	CcSEcCtD
Gliclazide—Hypersensitivity—Vincristine—kidney cancer	7.89e-05	0.000362	CcSEcCtD
Gliclazide—Nausea—Sorafenib—kidney cancer	7.81e-05	0.000359	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Paclitaxel—kidney cancer	7.75e-05	0.000356	CcSEcCtD
Gliclazide—Malaise—Capecitabine—kidney cancer	7.71e-05	0.000354	CcSEcCtD
Gliclazide—Angina pectoris—Doxorubicin—kidney cancer	7.7e-05	0.000354	CcSEcCtD
Gliclazide—Insomnia—Paclitaxel—kidney cancer	7.69e-05	0.000353	CcSEcCtD
Gliclazide—Asthenia—Vincristine—kidney cancer	7.68e-05	0.000353	CcSEcCtD
Gliclazide—Leukopenia—Capecitabine—kidney cancer	7.65e-05	0.000352	CcSEcCtD
Gliclazide—Paraesthesia—Paclitaxel—kidney cancer	7.63e-05	0.000351	CcSEcCtD
Gliclazide—Vomiting—Dactinomycin—kidney cancer	7.62e-05	0.00035	CcSEcCtD
Gliclazide—Bronchitis—Doxorubicin—kidney cancer	7.61e-05	0.00035	CcSEcCtD
Gliclazide—Dyspnoea—Paclitaxel—kidney cancer	7.58e-05	0.000348	CcSEcCtD
Gliclazide—Somnolence—Paclitaxel—kidney cancer	7.56e-05	0.000347	CcSEcCtD
Gliclazide—Palpitations—Capecitabine—kidney cancer	7.55e-05	0.000347	CcSEcCtD
Gliclazide—Rash—Dactinomycin—kidney cancer	7.55e-05	0.000347	CcSEcCtD
Gliclazide—Nausea—Sunitinib—kidney cancer	7.52e-05	0.000345	CcSEcCtD
Gliclazide—Loss of consciousness—Capecitabine—kidney cancer	7.51e-05	0.000345	CcSEcCtD
Gliclazide—Pancytopenia—Doxorubicin—kidney cancer	7.51e-05	0.000345	CcSEcCtD
Gliclazide—Dyspepsia—Paclitaxel—kidney cancer	7.48e-05	0.000344	CcSEcCtD
Gliclazide—Cough—Capecitabine—kidney cancer	7.46e-05	0.000343	CcSEcCtD
Gliclazide—Hypertension—Capecitabine—kidney cancer	7.38e-05	0.000339	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Doxorubicin—kidney cancer	7.35e-05	0.000338	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Paclitaxel—kidney cancer	7.34e-05	0.000337	CcSEcCtD
Gliclazide—Fatigue—Paclitaxel—kidney cancer	7.33e-05	0.000337	CcSEcCtD
Gliclazide—Diarrhoea—Vincristine—kidney cancer	7.32e-05	0.000337	CcSEcCtD
Gliclazide—Asthenia—Gemcitabine—kidney cancer	7.29e-05	0.000335	CcSEcCtD
Gliclazide—Myalgia—Capecitabine—kidney cancer	7.28e-05	0.000334	CcSEcCtD
Gliclazide—Arthralgia—Capecitabine—kidney cancer	7.28e-05	0.000334	CcSEcCtD
Gliclazide—Chest pain—Capecitabine—kidney cancer	7.28e-05	0.000334	CcSEcCtD
Gliclazide—Pain—Paclitaxel—kidney cancer	7.27e-05	0.000334	CcSEcCtD
Gliclazide—Constipation—Paclitaxel—kidney cancer	7.27e-05	0.000334	CcSEcCtD
Gliclazide—Anxiety—Capecitabine—kidney cancer	7.25e-05	0.000333	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	7.23e-05	0.000332	CcSEcCtD
Gliclazide—Photosensitivity reaction—Doxorubicin—kidney cancer	7.22e-05	0.000332	CcSEcCtD
Gliclazide—Weight increased—Doxorubicin—kidney cancer	7.2e-05	0.000331	CcSEcCtD
Gliclazide—Discomfort—Capecitabine—kidney cancer	7.19e-05	0.00033	CcSEcCtD
Gliclazide—Pruritus—Gemcitabine—kidney cancer	7.18e-05	0.00033	CcSEcCtD
Gliclazide—Hyperglycaemia—Doxorubicin—kidney cancer	7.13e-05	0.000328	CcSEcCtD
Gliclazide—Dry mouth—Capecitabine—kidney cancer	7.12e-05	0.000327	CcSEcCtD
Gliclazide—Nausea—Dactinomycin—kidney cancer	7.12e-05	0.000327	CcSEcCtD
Gliclazide—Pneumonia—Doxorubicin—kidney cancer	7.09e-05	0.000326	CcSEcCtD
Gliclazide—Dizziness—Vincristine—kidney cancer	7.08e-05	0.000325	CcSEcCtD
Gliclazide—Drowsiness—Doxorubicin—kidney cancer	7.05e-05	0.000324	CcSEcCtD
Gliclazide—Confusional state—Capecitabine—kidney cancer	7.04e-05	0.000323	CcSEcCtD
Gliclazide—Feeling abnormal—Paclitaxel—kidney cancer	7.01e-05	0.000322	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	6.99e-05	0.000321	CcSEcCtD
Gliclazide—Gastrointestinal pain—Paclitaxel—kidney cancer	6.95e-05	0.000319	CcSEcCtD
Gliclazide—Diarrhoea—Gemcitabine—kidney cancer	6.95e-05	0.000319	CcSEcCtD
Gliclazide—Renal failure—Doxorubicin—kidney cancer	6.93e-05	0.000319	CcSEcCtD
Gliclazide—Infection—Capecitabine—kidney cancer	6.93e-05	0.000319	CcSEcCtD
Gliclazide—Neuropathy peripheral—Doxorubicin—kidney cancer	6.91e-05	0.000318	CcSEcCtD
Gliclazide—Jaundice—Doxorubicin—kidney cancer	6.87e-05	0.000316	CcSEcCtD
Gliclazide—Conjunctivitis—Doxorubicin—kidney cancer	6.85e-05	0.000315	CcSEcCtD
Gliclazide—Urinary tract infection—Doxorubicin—kidney cancer	6.85e-05	0.000315	CcSEcCtD
Gliclazide—Nervous system disorder—Capecitabine—kidney cancer	6.84e-05	0.000314	CcSEcCtD
Gliclazide—Thrombocytopenia—Capecitabine—kidney cancer	6.83e-05	0.000314	CcSEcCtD
Gliclazide—Tachycardia—Capecitabine—kidney cancer	6.81e-05	0.000313	CcSEcCtD
Gliclazide—Vomiting—Vincristine—kidney cancer	6.81e-05	0.000313	CcSEcCtD
Gliclazide—Skin disorder—Capecitabine—kidney cancer	6.78e-05	0.000311	CcSEcCtD
Gliclazide—Sweating—Doxorubicin—kidney cancer	6.76e-05	0.000311	CcSEcCtD
Gliclazide—Urticaria—Paclitaxel—kidney cancer	6.75e-05	0.00031	CcSEcCtD
Gliclazide—Rash—Vincristine—kidney cancer	6.75e-05	0.00031	CcSEcCtD
Gliclazide—Hyperhidrosis—Capecitabine—kidney cancer	6.75e-05	0.00031	CcSEcCtD
Gliclazide—Dermatitis—Vincristine—kidney cancer	6.74e-05	0.00031	CcSEcCtD
Gliclazide—Abdominal pain—Paclitaxel—kidney cancer	6.72e-05	0.000309	CcSEcCtD
Gliclazide—Body temperature increased—Paclitaxel—kidney cancer	6.72e-05	0.000309	CcSEcCtD
Gliclazide—Headache—Vincristine—kidney cancer	6.71e-05	0.000308	CcSEcCtD
Gliclazide—Hepatobiliary disease—Doxorubicin—kidney cancer	6.67e-05	0.000306	CcSEcCtD
Gliclazide—Epistaxis—Doxorubicin—kidney cancer	6.65e-05	0.000306	CcSEcCtD
Gliclazide—Sinusitis—Doxorubicin—kidney cancer	6.62e-05	0.000304	CcSEcCtD
Gliclazide—Agranulocytosis—Doxorubicin—kidney cancer	6.58e-05	0.000302	CcSEcCtD
Gliclazide—Hypotension—Capecitabine—kidney cancer	6.52e-05	0.0003	CcSEcCtD
Gliclazide—Vomiting—Gemcitabine—kidney cancer	6.46e-05	0.000297	CcSEcCtD
Gliclazide—Bradycardia—Doxorubicin—kidney cancer	6.44e-05	0.000296	CcSEcCtD
Gliclazide—Rash—Gemcitabine—kidney cancer	6.4e-05	0.000294	CcSEcCtD
Gliclazide—Dermatitis—Gemcitabine—kidney cancer	6.4e-05	0.000294	CcSEcCtD
Gliclazide—Headache—Gemcitabine—kidney cancer	6.36e-05	0.000292	CcSEcCtD
Gliclazide—Nausea—Vincristine—kidney cancer	6.36e-05	0.000292	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Capecitabine—kidney cancer	6.36e-05	0.000292	CcSEcCtD
Gliclazide—Rhinitis—Doxorubicin—kidney cancer	6.35e-05	0.000292	CcSEcCtD
Gliclazide—Hepatitis—Doxorubicin—kidney cancer	6.33e-05	0.000291	CcSEcCtD
Gliclazide—Insomnia—Capecitabine—kidney cancer	6.31e-05	0.00029	CcSEcCtD
Gliclazide—Hypoaesthesia—Doxorubicin—kidney cancer	6.3e-05	0.000289	CcSEcCtD
Gliclazide—Pharyngitis—Doxorubicin—kidney cancer	6.28e-05	0.000289	CcSEcCtD
Gliclazide—Paraesthesia—Capecitabine—kidney cancer	6.27e-05	0.000288	CcSEcCtD
Gliclazide—Hypersensitivity—Paclitaxel—kidney cancer	6.26e-05	0.000288	CcSEcCtD
Gliclazide—Oedema peripheral—Doxorubicin—kidney cancer	6.24e-05	0.000287	CcSEcCtD
Gliclazide—Dyspnoea—Capecitabine—kidney cancer	6.22e-05	0.000286	CcSEcCtD
Gliclazide—Dyspepsia—Capecitabine—kidney cancer	6.14e-05	0.000282	CcSEcCtD
Gliclazide—Visual impairment—Doxorubicin—kidney cancer	6.1e-05	0.00028	CcSEcCtD
Gliclazide—Asthenia—Paclitaxel—kidney cancer	6.1e-05	0.00028	CcSEcCtD
Gliclazide—Nausea—Gemcitabine—kidney cancer	6.03e-05	0.000277	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Capecitabine—kidney cancer	6.02e-05	0.000277	CcSEcCtD
Gliclazide—Fatigue—Capecitabine—kidney cancer	6.02e-05	0.000276	CcSEcCtD
Gliclazide—Pruritus—Paclitaxel—kidney cancer	6.02e-05	0.000276	CcSEcCtD
Gliclazide—Erythema multiforme—Doxorubicin—kidney cancer	5.99e-05	0.000275	CcSEcCtD
Gliclazide—Pain—Capecitabine—kidney cancer	5.97e-05	0.000274	CcSEcCtD
Gliclazide—Constipation—Capecitabine—kidney cancer	5.97e-05	0.000274	CcSEcCtD
Gliclazide—Eye disorder—Doxorubicin—kidney cancer	5.92e-05	0.000272	CcSEcCtD
Gliclazide—Tinnitus—Doxorubicin—kidney cancer	5.9e-05	0.000271	CcSEcCtD
Gliclazide—Flushing—Doxorubicin—kidney cancer	5.88e-05	0.00027	CcSEcCtD
Gliclazide—Diarrhoea—Paclitaxel—kidney cancer	5.82e-05	0.000267	CcSEcCtD
Gliclazide—Feeling abnormal—Capecitabine—kidney cancer	5.75e-05	0.000264	CcSEcCtD
Gliclazide—Gastrointestinal pain—Capecitabine—kidney cancer	5.71e-05	0.000262	CcSEcCtD
Gliclazide—Chills—Doxorubicin—kidney cancer	5.68e-05	0.000261	CcSEcCtD
Gliclazide—Arrhythmia—Doxorubicin—kidney cancer	5.66e-05	0.00026	CcSEcCtD
Gliclazide—Dizziness—Paclitaxel—kidney cancer	5.62e-05	0.000258	CcSEcCtD
Gliclazide—Mental disorder—Doxorubicin—kidney cancer	5.55e-05	0.000255	CcSEcCtD
Gliclazide—Urticaria—Capecitabine—kidney cancer	5.54e-05	0.000255	CcSEcCtD
Gliclazide—Body temperature increased—Capecitabine—kidney cancer	5.52e-05	0.000253	CcSEcCtD
Gliclazide—Abdominal pain—Capecitabine—kidney cancer	5.52e-05	0.000253	CcSEcCtD
Gliclazide—Malnutrition—Doxorubicin—kidney cancer	5.51e-05	0.000253	CcSEcCtD
Gliclazide—Erythema—Doxorubicin—kidney cancer	5.51e-05	0.000253	CcSEcCtD
Gliclazide—Flatulence—Doxorubicin—kidney cancer	5.43e-05	0.00025	CcSEcCtD
Gliclazide—Tension—Doxorubicin—kidney cancer	5.41e-05	0.000248	CcSEcCtD
Gliclazide—Vomiting—Paclitaxel—kidney cancer	5.41e-05	0.000248	CcSEcCtD
Gliclazide—Rash—Paclitaxel—kidney cancer	5.36e-05	0.000246	CcSEcCtD
Gliclazide—Dermatitis—Paclitaxel—kidney cancer	5.36e-05	0.000246	CcSEcCtD
Gliclazide—Nervousness—Doxorubicin—kidney cancer	5.35e-05	0.000246	CcSEcCtD
Gliclazide—Back pain—Doxorubicin—kidney cancer	5.33e-05	0.000245	CcSEcCtD
Gliclazide—Headache—Paclitaxel—kidney cancer	5.33e-05	0.000245	CcSEcCtD
Gliclazide—Hypersensitivity—Capecitabine—kidney cancer	5.14e-05	0.000236	CcSEcCtD
Gliclazide—Ill-defined disorder—Doxorubicin—kidney cancer	5.11e-05	0.000235	CcSEcCtD
Gliclazide—Anaemia—Doxorubicin—kidney cancer	5.09e-05	0.000234	CcSEcCtD
Gliclazide—Agitation—Doxorubicin—kidney cancer	5.06e-05	0.000233	CcSEcCtD
Gliclazide—Nausea—Paclitaxel—kidney cancer	5.05e-05	0.000232	CcSEcCtD
Gliclazide—Asthenia—Capecitabine—kidney cancer	5.01e-05	0.00023	CcSEcCtD
Gliclazide—Malaise—Doxorubicin—kidney cancer	4.97e-05	0.000228	CcSEcCtD
Gliclazide—Pruritus—Capecitabine—kidney cancer	4.94e-05	0.000227	CcSEcCtD
Gliclazide—Leukopenia—Doxorubicin—kidney cancer	4.93e-05	0.000227	CcSEcCtD
Gliclazide—Palpitations—Doxorubicin—kidney cancer	4.87e-05	0.000224	CcSEcCtD
Gliclazide—Loss of consciousness—Doxorubicin—kidney cancer	4.84e-05	0.000223	CcSEcCtD
Gliclazide—Cough—Doxorubicin—kidney cancer	4.81e-05	0.000221	CcSEcCtD
Gliclazide—Convulsion—Doxorubicin—kidney cancer	4.77e-05	0.000219	CcSEcCtD
Gliclazide—Diarrhoea—Capecitabine—kidney cancer	4.77e-05	0.000219	CcSEcCtD
Gliclazide—Hypertension—Doxorubicin—kidney cancer	4.76e-05	0.000219	CcSEcCtD
Gliclazide—Chest pain—Doxorubicin—kidney cancer	4.69e-05	0.000216	CcSEcCtD
Gliclazide—Arthralgia—Doxorubicin—kidney cancer	4.69e-05	0.000216	CcSEcCtD
Gliclazide—Myalgia—Doxorubicin—kidney cancer	4.69e-05	0.000216	CcSEcCtD
Gliclazide—Anxiety—Doxorubicin—kidney cancer	4.68e-05	0.000215	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	4.66e-05	0.000214	CcSEcCtD
Gliclazide—Discomfort—Doxorubicin—kidney cancer	4.64e-05	0.000213	CcSEcCtD
Gliclazide—Dizziness—Capecitabine—kidney cancer	4.61e-05	0.000212	CcSEcCtD
Gliclazide—Dry mouth—Doxorubicin—kidney cancer	4.59e-05	0.000211	CcSEcCtD
Gliclazide—Confusional state—Doxorubicin—kidney cancer	4.53e-05	0.000208	CcSEcCtD
Gliclazide—Infection—Doxorubicin—kidney cancer	4.47e-05	0.000205	CcSEcCtD
Gliclazide—Vomiting—Capecitabine—kidney cancer	4.44e-05	0.000204	CcSEcCtD
Gliclazide—Nervous system disorder—Doxorubicin—kidney cancer	4.41e-05	0.000203	CcSEcCtD
Gliclazide—Thrombocytopenia—Doxorubicin—kidney cancer	4.4e-05	0.000202	CcSEcCtD
Gliclazide—Rash—Capecitabine—kidney cancer	4.4e-05	0.000202	CcSEcCtD
Gliclazide—Dermatitis—Capecitabine—kidney cancer	4.4e-05	0.000202	CcSEcCtD
Gliclazide—Tachycardia—Doxorubicin—kidney cancer	4.39e-05	0.000202	CcSEcCtD
Gliclazide—Headache—Capecitabine—kidney cancer	4.37e-05	0.000201	CcSEcCtD
Gliclazide—Skin disorder—Doxorubicin—kidney cancer	4.37e-05	0.000201	CcSEcCtD
Gliclazide—Hyperhidrosis—Doxorubicin—kidney cancer	4.35e-05	0.0002	CcSEcCtD
Gliclazide—Hypotension—Doxorubicin—kidney cancer	4.2e-05	0.000193	CcSEcCtD
Gliclazide—Nausea—Capecitabine—kidney cancer	4.14e-05	0.00019	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Doxorubicin—kidney cancer	4.1e-05	0.000188	CcSEcCtD
Gliclazide—Insomnia—Doxorubicin—kidney cancer	4.07e-05	0.000187	CcSEcCtD
Gliclazide—Paraesthesia—Doxorubicin—kidney cancer	4.04e-05	0.000186	CcSEcCtD
Gliclazide—Dyspnoea—Doxorubicin—kidney cancer	4.01e-05	0.000184	CcSEcCtD
Gliclazide—Somnolence—Doxorubicin—kidney cancer	4e-05	0.000184	CcSEcCtD
Gliclazide—Dyspepsia—Doxorubicin—kidney cancer	3.96e-05	0.000182	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Doxorubicin—kidney cancer	3.88e-05	0.000178	CcSEcCtD
Gliclazide—Fatigue—Doxorubicin—kidney cancer	3.88e-05	0.000178	CcSEcCtD
Gliclazide—Constipation—Doxorubicin—kidney cancer	3.85e-05	0.000177	CcSEcCtD
Gliclazide—Pain—Doxorubicin—kidney cancer	3.85e-05	0.000177	CcSEcCtD
Gliclazide—KCNJ11—Neuronal System—MAPK1—kidney cancer	3.78e-05	0.000317	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ACHE—kidney cancer	3.74e-05	0.000313	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTT1—kidney cancer	3.74e-05	0.000313	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—GSTM1—kidney cancer	3.74e-05	0.000313	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	3.72e-05	0.000312	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—MAPK1—kidney cancer	3.72e-05	0.000312	CbGpPWpGaD
Gliclazide—Feeling abnormal—Doxorubicin—kidney cancer	3.71e-05	0.00017	CcSEcCtD
Gliclazide—Gastrointestinal pain—Doxorubicin—kidney cancer	3.68e-05	0.000169	CcSEcCtD
Gliclazide—ABCC8—Metabolism—SCARB1—kidney cancer	3.65e-05	0.000306	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—GRB7—kidney cancer	3.61e-05	0.000303	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—kidney cancer	3.61e-05	0.000303	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS1—kidney cancer	3.61e-05	0.000303	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—CYP1A1—kidney cancer	3.59e-05	0.000301	CbGpPWpGaD
Gliclazide—Urticaria—Doxorubicin—kidney cancer	3.57e-05	0.000164	CcSEcCtD
Gliclazide—Body temperature increased—Doxorubicin—kidney cancer	3.56e-05	0.000163	CcSEcCtD
Gliclazide—Abdominal pain—Doxorubicin—kidney cancer	3.56e-05	0.000163	CcSEcCtD
Gliclazide—CYP2C9—Metapathway biotransformation—CYP1A1—kidney cancer	3.54e-05	0.000297	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PSMD7—kidney cancer	3.54e-05	0.000297	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—SCARB1—kidney cancer	3.54e-05	0.000297	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS1—kidney cancer	3.5e-05	0.000294	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GRB7—kidney cancer	3.47e-05	0.000291	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ACY1—kidney cancer	3.46e-05	0.00029	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PSMD7—kidney cancer	3.43e-05	0.000288	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—ITPR2—kidney cancer	3.36e-05	0.000282	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—BCHE—kidney cancer	3.36e-05	0.000281	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TP53—kidney cancer	3.34e-05	0.00028	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MAPK3—kidney cancer	3.32e-05	0.000278	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—SLC5A5—kidney cancer	3.32e-05	0.000278	CbGpPWpGaD
Gliclazide—Hypersensitivity—Doxorubicin—kidney cancer	3.31e-05	0.000152	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	3.29e-05	0.000276	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—RAF1—kidney cancer	3.29e-05	0.000276	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PDHB—kidney cancer	3.28e-05	0.000275	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—RELA—kidney cancer	3.27e-05	0.000274	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—BCHE—kidney cancer	3.25e-05	0.000273	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—ERBB2—kidney cancer	3.25e-05	0.000273	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ITPR2—kidney cancer	3.23e-05	0.000271	CbGpPWpGaD
Gliclazide—Asthenia—Doxorubicin—kidney cancer	3.23e-05	0.000148	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—RAF1—kidney cancer	3.22e-05	0.00027	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—SLC5A5—kidney cancer	3.21e-05	0.00027	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—SLC2A1—kidney cancer	3.2e-05	0.000269	CbGpPWpGaD
Gliclazide—Pruritus—Doxorubicin—kidney cancer	3.18e-05	0.000146	CcSEcCtD
Gliclazide—CYP2C9—Metabolism—ACY1—kidney cancer	3.16e-05	0.000265	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MAPK1—kidney cancer	3.16e-05	0.000265	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—TP53—kidney cancer	3.12e-05	0.000262	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—SLC2A1—kidney cancer	3.1e-05	0.00026	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CCBL1—kidney cancer	3.08e-05	0.000259	CbGpPWpGaD
Gliclazide—Diarrhoea—Doxorubicin—kidney cancer	3.08e-05	0.000141	CcSEcCtD
Gliclazide—ABCC8—Transmembrane transport of small molecules—RAF1—kidney cancer	3.05e-05	0.000256	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—KRAS—kidney cancer	2.98e-05	0.00025	CbGpPWpGaD
Gliclazide—Dizziness—Doxorubicin—kidney cancer	2.97e-05	0.000137	CcSEcCtD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	2.95e-05	0.000248	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PDHB—kidney cancer	2.95e-05	0.000247	CbGpPWpGaD
Gliclazide—CYP2C19—Biological oxidations—POMC—kidney cancer	2.94e-05	0.000246	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CTNNA1—kidney cancer	2.93e-05	0.000245	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HSPB1—kidney cancer	2.91e-05	0.000244	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EIF4EBP1—kidney cancer	2.91e-05	0.000244	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IL2—kidney cancer	2.89e-05	0.000242	CbGpPWpGaD
Gliclazide—Vomiting—Doxorubicin—kidney cancer	2.86e-05	0.000131	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—CTNNB1—kidney cancer	2.84e-05	0.000238	CbGpPWpGaD
Gliclazide—Rash—Doxorubicin—kidney cancer	2.84e-05	0.00013	CcSEcCtD
Gliclazide—Dermatitis—Doxorubicin—kidney cancer	2.83e-05	0.00013	CcSEcCtD
Gliclazide—Headache—Doxorubicin—kidney cancer	2.82e-05	0.000129	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.79e-05	0.000234	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CCBL1—kidney cancer	2.77e-05	0.000232	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PSMD7—kidney cancer	2.7e-05	0.000227	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TSC1—kidney cancer	2.7e-05	0.000227	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ANXA1—kidney cancer	2.7e-05	0.000227	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	2.69e-05	0.000226	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PDHB—kidney cancer	2.69e-05	0.000225	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—POMC—kidney cancer	2.68e-05	0.000224	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GLIPR1—kidney cancer	2.67e-05	0.000224	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPAT—kidney cancer	2.67e-05	0.000224	CbGpPWpGaD
Gliclazide—Nausea—Doxorubicin—kidney cancer	2.67e-05	0.000123	CcSEcCtD
Gliclazide—ABCC8—Metabolism—GSTP1—kidney cancer	2.67e-05	0.000224	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.64e-05	0.000221	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FLT1—kidney cancer	2.62e-05	0.00022	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.61e-05	0.000219	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTP1—kidney cancer	2.59e-05	0.000217	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ABCB1—kidney cancer	2.53e-05	0.000212	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CCBL1—kidney cancer	2.52e-05	0.000212	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.5e-05	0.00021	CbGpPWpGaD
Gliclazide—ALB—Metabolism—FH—kidney cancer	2.49e-05	0.000209	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APRT—kidney cancer	2.49e-05	0.000209	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IFNA1—kidney cancer	2.47e-05	0.000207	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GSTM1—kidney cancer	2.45e-05	0.000206	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ABCB1—kidney cancer	2.45e-05	0.000206	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.43e-05	0.000204	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JUNB—kidney cancer	2.43e-05	0.000204	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PAK1—kidney cancer	2.43e-05	0.000204	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPAT—kidney cancer	2.4e-05	0.000201	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GLIPR1—kidney cancer	2.4e-05	0.000201	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTM1—kidney cancer	2.38e-05	0.0002	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.37e-05	0.000199	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MAPK3—kidney cancer	2.37e-05	0.000199	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.35e-05	0.000197	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GPC3—kidney cancer	2.34e-05	0.000196	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CYP1A1—kidney cancer	2.33e-05	0.000195	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—MAPK3—kidney cancer	2.32e-05	0.000195	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IFNA2—kidney cancer	2.3e-05	0.000192	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.28e-05	0.000191	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC5A5—kidney cancer	2.28e-05	0.000191	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CA2—kidney cancer	2.27e-05	0.000191	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CYP1A1—kidney cancer	2.26e-05	0.000189	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MAPK1—kidney cancer	2.25e-05	0.000189	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—FH—kidney cancer	2.23e-05	0.000187	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APRT—kidney cancer	2.23e-05	0.000187	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALAD—kidney cancer	2.22e-05	0.000186	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—MAPK1—kidney cancer	2.21e-05	0.000185	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—RAF1—kidney cancer	2.21e-05	0.000185	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC2A1—kidney cancer	2.2e-05	0.000185	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GLIPR1—kidney cancer	2.19e-05	0.000184	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPAT—kidney cancer	2.19e-05	0.000184	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.18e-05	0.000183	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ST3GAL2—kidney cancer	2.16e-05	0.000181	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.16e-05	0.000181	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.14e-05	0.000179	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—KRAS—kidney cancer	2.13e-05	0.000178	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALDH1A1—kidney cancer	2.11e-05	0.000177	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GPC3—kidney cancer	2.1e-05	0.000176	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—KRAS—kidney cancer	2.09e-05	0.000175	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IGF2—kidney cancer	2.07e-05	0.000173	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CA2—kidney cancer	2.04e-05	0.000171	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—FH—kidney cancer	2.04e-05	0.000171	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APRT—kidney cancer	2.04e-05	0.000171	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PGK1—kidney cancer	2.03e-05	0.00017	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SLC5A3—kidney cancer	2.03e-05	0.00017	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALAD—kidney cancer	1.99e-05	0.000167	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	1.99e-05	0.000167	CbGpPWpGaD
Gliclazide—ALB—Metabolism—LDHB—kidney cancer	1.99e-05	0.000167	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IGF2—kidney cancer	1.99e-05	0.000166	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IL2—kidney cancer	1.98e-05	0.000166	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN2B—kidney cancer	1.98e-05	0.000166	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ST3GAL2—kidney cancer	1.94e-05	0.000163	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IGF1R—kidney cancer	1.92e-05	0.000161	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PIK3CA—kidney cancer	1.92e-05	0.000161	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GPC3—kidney cancer	1.91e-05	0.00016	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALDH1A1—kidney cancer	1.9e-05	0.000159	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CA2—kidney cancer	1.86e-05	0.000156	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—kidney cancer	1.86e-05	0.000156	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC5A3—kidney cancer	1.82e-05	0.000153	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PGK1—kidney cancer	1.82e-05	0.000153	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALAD—kidney cancer	1.81e-05	0.000152	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—LDHB—kidney cancer	1.78e-05	0.00015	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ST3GAL2—kidney cancer	1.77e-05	0.000148	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.74e-05	0.000146	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—POMC—kidney cancer	1.73e-05	0.000145	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALDH1A1—kidney cancer	1.73e-05	0.000145	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CA9—kidney cancer	1.72e-05	0.000145	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.68e-05	0.000141	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—POMC—kidney cancer	1.68e-05	0.000141	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—kidney cancer	1.68e-05	0.000141	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PGK1—kidney cancer	1.66e-05	0.000139	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC5A3—kidney cancer	1.66e-05	0.000139	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—LDHB—kidney cancer	1.63e-05	0.000136	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—MAPK3—kidney cancer	1.59e-05	0.000133	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HIF1A—kidney cancer	1.58e-05	0.000133	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TSC2—kidney cancer	1.58e-05	0.000132	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CA9—kidney cancer	1.55e-05	0.00013	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—MAPK1—kidney cancer	1.51e-05	0.000127	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.51e-05	0.000127	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KDR—kidney cancer	1.51e-05	0.000127	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CRABP1—kidney cancer	1.47e-05	0.000123	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CA9—kidney cancer	1.41e-05	0.000118	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KIT—kidney cancer	1.39e-05	0.000117	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APC—kidney cancer	1.39e-05	0.000117	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—kidney cancer	1.38e-05	0.000116	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.38e-05	0.000116	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ITPR2—kidney cancer	1.36e-05	0.000114	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—kidney cancer	1.34e-05	0.000113	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—POMC—kidney cancer	1.33e-05	0.000111	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CRABP1—kidney cancer	1.32e-05	0.00011	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	1.31e-05	0.00011	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—BRAF—kidney cancer	1.31e-05	0.00011	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.26e-05	0.000105	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ACHE—kidney cancer	1.24e-05	0.000104	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTT1—kidney cancer	1.24e-05	0.000104	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ITPR2—kidney cancer	1.22e-05	0.000103	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTEN—kidney cancer	1.21e-05	0.000101	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CRABP1—kidney cancer	1.2e-05	0.000101	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SCARB1—kidney cancer	1.18e-05	9.86e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTEN—kidney cancer	1.17e-05	9.81e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS1—kidney cancer	1.16e-05	9.76e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PSMD7—kidney cancer	1.14e-05	9.57e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—RAF1—kidney cancer	1.14e-05	9.54e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.13e-05	9.45e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ACHE—kidney cancer	1.12e-05	9.35e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTT1—kidney cancer	1.12e-05	9.35e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ITPR2—kidney cancer	1.12e-05	9.35e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RAF1—kidney cancer	1.09e-05	9.16e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RELA—kidney cancer	1.09e-05	9.12e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—BCHE—kidney cancer	1.08e-05	9.08e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ERBB2—kidney cancer	1.08e-05	9.07e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SLC5A5—kidney cancer	1.07e-05	8.96e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MTOR—kidney cancer	1.07e-05	8.95e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SCARB1—kidney cancer	1.06e-05	8.85e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS1—kidney cancer	1.04e-05	8.76e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SLC2A1—kidney cancer	1.03e-05	8.66e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.03e-05	8.62e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PSMD7—kidney cancer	1.02e-05	8.59e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL2—kidney cancer	1.02e-05	8.55e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTT1—kidney cancer	1.02e-05	8.53e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ACHE—kidney cancer	1.02e-05	8.53e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1e-05	8.4e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1B—kidney cancer	1e-05	8.4e-05	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—RAF1—kidney cancer	9.85e-06	8.26e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2—kidney cancer	9.8e-06	8.22e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—BCHE—kidney cancer	9.71e-06	8.15e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SCARB1—kidney cancer	9.63e-06	8.07e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC5A5—kidney cancer	9.6e-06	8.05e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCND1—kidney cancer	9.55e-06	8.01e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JUN—kidney cancer	9.53e-06	7.99e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS1—kidney cancer	9.53e-06	7.99e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CTNNB1—kidney cancer	9.46e-06	7.93e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PSMD7—kidney cancer	9.34e-06	7.84e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC2A1—kidney cancer	9.27e-06	7.77e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTEN—kidney cancer	9.22e-06	7.73e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	8.99e-06	7.54e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—BCHE—kidney cancer	8.86e-06	7.43e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC5A5—kidney cancer	8.75e-06	7.34e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	8.74e-06	7.33e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—kidney cancer	8.67e-06	7.27e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTP1—kidney cancer	8.61e-06	7.22e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CA—kidney cancer	8.51e-06	7.14e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC2A1—kidney cancer	8.45e-06	7.09e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CA—kidney cancer	8.25e-06	6.92e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	8.2e-06	6.88e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MAPK3—kidney cancer	8.2e-06	6.88e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ABCB1—kidney cancer	8.15e-06	6.84e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTM1—kidney cancer	7.91e-06	6.64e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK3—kidney cancer	7.88e-06	6.61e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	7.84e-06	6.58e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MAPK1—kidney cancer	7.8e-06	6.54e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTP1—kidney cancer	7.73e-06	6.48e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—kidney cancer	7.66e-06	6.42e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP1A1—kidney cancer	7.5e-06	6.29e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK1—kidney cancer	7.49e-06	6.28e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KRAS—kidney cancer	7.37e-06	6.18e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCB1—kidney cancer	7.32e-06	6.14e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	7.15e-06	6e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTM1—kidney cancer	7.1e-06	5.96e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KRAS—kidney cancer	7.08e-06	5.94e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTP1—kidney cancer	7.05e-06	5.91e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CA—kidney cancer	6.77e-06	5.68e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP1A1—kidney cancer	6.73e-06	5.65e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCB1—kidney cancer	6.67e-06	5.6e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—kidney cancer	6.55e-06	5.49e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CA—kidney cancer	6.5e-06	5.45e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTM1—kidney cancer	6.48e-06	5.43e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—kidney cancer	6.29e-06	5.28e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.16e-06	5.17e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP1A1—kidney cancer	6.14e-06	5.15e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—POMC—kidney cancer	5.59e-06	4.69e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.53e-06	4.64e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.04e-06	4.23e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—POMC—kidney cancer	5.02e-06	4.21e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—POMC—kidney cancer	4.58e-06	3.84e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—kidney cancer	4.46e-06	3.74e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—kidney cancer	4e-06	3.36e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTEN—kidney cancer	3.89e-06	3.26e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—kidney cancer	3.65e-06	3.06e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTEN—kidney cancer	3.49e-06	2.93e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTEN—kidney cancer	3.18e-06	2.67e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CA—kidney cancer	2.74e-06	2.3e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CA—kidney cancer	2.46e-06	2.07e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CA—kidney cancer	2.25e-06	1.88e-05	CbGpPWpGaD
